Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Oxalate Excretion of FB-001 in Healthy Volunteers and Enteric Hyperoxaluria
NCT05650112Phase 1Unknown
- Sponsor
- Federation Bio
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FB-001 in enteric hyperoxaluria (EH) (3 arms), sponsored by Federation Bio. Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events at 196 days. Status: unknown.
02
Drugs
FB-001
03
Conditions
enteric hyperoxaluria (EH)
Beyond the preview
Go deeper on NCT05650112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650112.